The timing of glucocorticoid administration in rheumatoid arthritis
Open Access
- 1 January 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 56 (1) , 27-31
- https://doi.org/10.1136/ard.56.1.27
Abstract
OBJECTIVE To test the hypothesis that the timing of prednisolone administration might be critical in determining its effect on the diurnal rheumatoid inflammatory process. METHODS 26 patients with rheumatoid arthritis were randomly divided into two equal groups and allocated to low doses of prednisolone at either 2.00 am or 7.30 am. Because of the diurnal variation in disease activity in rheumatoid arthritis, assessments of the two study groups were performed at 7.30 am both at the start of the study (day 1) and after four doses of prednisolone (day 5). The study protocol differences in the time period from the last dose of prednisolone to assessment were 5.5 hours in the 2.00 am group and 24 hours in the 7.30 am group. RESULTS Administration of low doses of prednisolone (5 or 7.5 mg daily) at 2.00 am had favourable effects on the duration of morning stiffness (P << 0.001), joint pain (P < 0.001), Lansbury index (P << 0.001), Ritchie index (P << 0.001), and morning serum concentrations of IL-6 (P < 0.01). The other study group showed minor but significant effects on morning stiffness (P < 0.05) and circulating concentrations of IL-6 (P < 0.05). Modest and similar improvements of C reactive protein, serum amyloid protein A, and erythrocyte sedimentation rate were seen in both study groups. CONCLUSIONS Administration of low doses of glucocorticoids with a rather short biological half life seems to improve acute rheumatoid arthritis symptoms if it precedes the period of circadian flare in inflammatory activity, as defined by enhanced IL-6 synthesis. Further studies are needed to test the relative merits of different timing protocols of glucocorticoid administration in rheumatoid arthritis.Keywords
This publication has 38 references indexed in Scilit:
- INTERLEUKIN-6 (IL-6) INDUCES THE PROLIFERATION OF SYNOVIAL FIBROBLASTIC CELLS IN THE PRESENCE OF SOLUBLE IL-6 RECEPTORRheumatology, 1995
- Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid.Annals of the Rheumatic Diseases, 1995
- Circadian rhythm of serum interleukin-6 in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1994
- EVIDENCE THAT GLUCOCORTICOSTEROIDS BLOCK EXPRESSION OF THE HUMAN INTERLEUKIN-6 GENE BY ACCESSORY CELLSTransplantation, 1990
- Regulation of synthesis and secretion of major rat acute‐phase proteins by recombinant human interleukin‐6 (BSF‐2/1L‐6) in hepatocyte primary culturesEuropean Journal of Biochemistry, 1988
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute‐phase responseArthritis & Rheumatism, 1987
- Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoidsMetabolic Bone Disease and Related Research, 1984
- Clinical Pharmacokinetics of Prednisone and PrednisoloneClinical Pharmacokinetics, 1979
- Adrenocortical Hormone in ArthritisAnnals of the Rheumatic Diseases, 1949